Table 1:

Demographic and TB-related characteristics of children with and without treatment delays

	Children with delay*	Children without delay
	n=11	n=15
Age, median [range]	2.5 [0.9-14.9]	5.3 [0.6-14.8]
Female sex, n (%)	5 (45%)	10 (67%)
Days from diagnosis to treatment initiation, median [range]**	26 [7-117]	1 [0-6]
Case status, n (%)
Culture-confirmed TB	4 (36%)	6 (40%)
Clinically-diagnosed, unconfirmed TB	7 (64%)	9 (60%)
Received a regimen other than HREZ, n (%)**	5 (42%)	1 (7%)
Other regimen received n (%)
PAS/AMK/CS/ETO/LFX	0 (0%)	1 (7%)***
AMK/CS/ETO/LFX/PZA	1 (9%)	0 (0%)
EMB/LFX/PZA/RIF	2 (18%)	0 (0%)
CS/EMB/ETO/KM/LFX/PZA	2 (18%)	0 (0%)

^*Delay defined as time lapse of seven or more days between diagnosis to treatment start, as documented in the child’s medical record

^**N=25. One child with a TB treatment delay did not start treatment until after study closure. We were therefore unable to obtain data on date of treatment initiation and regimen.

^***This case represents an exception to committee review for drug resistant cases: due to known MDR-TB in both parents, that drugs happened to be available at the clinic and the attending physician was a member of the national committee of experts, the child was able to start treatment quickly